Ibandronic Acid
This is the acid form of ibandronate, a bisphosphonate medication that prevents bone loss by inhibiting the bone-resorbing activity of osteoclasts. It is used to treat osteoporosis, reduce fracture risk, and manage hypercalcemia of malignancy and bone metastases. Patients taking oral forms should remain upright after swallowing to minimize esophageal irritation.
Peso molecular
319,2300 g/mol
LogP
-4,10
TPSA
139,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
Molecular Formula
C9H23NO7P2
HBD / HBA
5 / 8
Enlaces Rotables
9
Átomos Pesados
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This is the acid form of ibandronate, a bisphosphonate medication that prevents bone loss by inhibiting the bone-resorbing activity of osteoclasts. It is used to treat osteoporosis, reduce fracture risk, and manage hypercalcemia of malignancy and bone metastases. Patients taking oral forms should remain upright after swallowing to minimize esophageal irritation.
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.
Yes, Ibandronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL997. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60852. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ibandronic-acid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ibandronic-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ibandronic-acid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ibandronic-acid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ibandronic-acid"></drugfyi-drug>